Bone Resorption Disorders
📧 Sign up to get email alerts when something new happens for Bone Resorption Disorders.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-24EMA Authorised: Izamby (denosumab) — Mabxience Research SL
EMA authorises Izamby (denosumab) for bone resorption disorders including osteoporosis and postmenopausal osteoporosis.
-
EMA approval · 2026-08-20EMA Authorised: Junod (denosumab) — Gedeon Richter Plc.
Authorisation of Junod (denosumab) by Gedeon Richter Plc. for conditions related to bone resorption and osteoporosis, including postmenopaus…
-
EMA approval · 2026-08-18EMA Authorised: Conexxence (denosumab) — Fresenius Kabi Deutschland GmbH
EMA authorised Conexxence (denosumab) for osteoporosis indications, including postmenopausal osteoporosis and bone resorption conditions.
-
EMA approval · 2026-07-14EMA Authorised: Bildyos (denosumab) — Sciencepharma Sp. z o.o
The EMA has authorised Bildyos (denosumab) by Sciencepharma Sp. z o.o. for bone resorption disorders including osteoporosis, including postm…
-
EMA approval · 2026-06-16EMA Authorised: Kefdensis (denosumab) — Stada Arzneimittel AG
Authorised status for Kefdensis (denosumab) by Stada Arzneimittel AG for bone resorption disorders including osteoporosis and postmenopausal…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA withdrawal · 2008-11-20EMA Withdrawn: Forcaltonin (recombinant salmon calcitonin) — Unigene UK Ltd.
Forcaltonin (recombinant salmon calcitonin) has been withdrawn from the EMA; previously indicated for hypercalcemia, osteitis deformans, and…